The transcription factor Nrf2 as a new therapeutic target in Parkinson's disease
The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
In recent years, it has been accepted that oxidative stress is critically involved in the etiopathology of Parkinson's disease (PD) and as a result new therapeutic targets for reduction of oxidant injury and neuroprotection can be defined. Here we discuss the potential use of the transcription factor nuclear factor erythroid-2-related factor 2 (Nrf2), as a pharmacological target for neuroprotective therapy in PD. Data generated by various groups indicate that Nrf2 induces the expression of a group of cytoprotective, antixenobiotic and antioxidant enzymes that include heme oxygenase-1, NAD(P)H:quinone oxidoreductase and enzymes of glutathione (GSH) metabolism such as gamma-glutamyl cysteine ligase, GSH transferases and so on. Two strategies are known to increase Nrf2 transcriptional activity in PD: i) use of certain catechol-derived quinones for selective inhibition of the Nrf2 repressor Kelch-like ECH-associated protein to increase of Nrf2 protein levels; and ii) use of glycogen synthase kinase 3beta inhibitors to maintain high protein and activity levels of Nrf2 in the nucleus. This review provides a rationale for drug design of appropriate molecules that might endorse a neuroprotective strategy to PD on the basis of attenuation of oxidative stress.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
Kobayashi, A., Kang, M.-I., Okawa, H., Ohtsuji, M., Zenke, Y., Chiba, T., Igarashi, K., & Yamamoto, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.16.7130-7139.2004 · Cited by 2,224 · cited 1×
“This is because it binds in the cytosol to a homodimeric protein, Keap1, which sequesters Nrf2 and presents it to a Cul3-based E3-ubiquitine ligase complex, resulting in Nrf2 ubiquitination and proteasomal degradation [39-42] .”
BackgroundDinkova-Kostova, A. T., Holtzclaw, W. D., Cole, R. N., Itoh, K., Wakabayashi, N., Katoh, Y., Yamamoto, M., & Talalay, P. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398899 · Cited by 1,947 · cited 1×
“Cysteines at positions 151, 273 and 288 seem to be particularly sensitive to redox changes and to interaction with electrophilic compounds [38,41,47-51] .”
BackgroundZhang, D. D., & Hannink, M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.22.8137-8151.2003 · Cited by 1,480 · cited 1×
“Cysteines at positions 151, 273 and 288 seem to be particularly sensitive to redox changes and to interaction with electrophilic compounds [38,41,47-51] .”
BackgroundIn vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease
Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., Eggert, K., Oertel, W., Banati, R. B., & Brooks, D. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.08.002 · Cited by 1,200 · cited 1×
“Proinflammatory cytokines accumulate in the cerebrospinal fluid of PD patients, and are increased in post-mortem brain samples and in experimental models of this disease [26] .”
BackgroundSian, J., Dexter, D. T., Lees, A. J., Daniel, S., Agid, Y., Javoy‐Agid, F., Jenner, P., & Marsden, C. D. (1994) · Annals of Neurology · doi:10.1002/ana.410360305 · Cited by 1,161
Kinetic Stabilization of the α-Synuclein Protofibril by a Dopamine-α-Synuclein Adduct
Conway, K. A., Rochet, J.-C., Bieganski, R. M., & Lansbury, P. T. (2001) · Science · doi:10.1126/science.1063522 · Cited by 1,127
Pharmacological and Clinical Aspects of Heme Oxygenase
Abraham, N. G., & Kappas, A. (2008) · Pharmacological Reviews · doi:10.1124/pr.107.07104 · Cited by 1,115
Catecholamine Metabolism: A Contemporary View with Implications for Physiology and Medicine
Eisenhofer, G., Kopin, I. J., & Goldstein, D. S. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.3.1 · Cited by 1,072 · cited 1×
“More than 90% of DA is stored in presynaptic vesicles [12] but the remaining small cytosolic fraction undergoes spontaneous or MAO-B mediated degradation to form 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) as well as superoxide, H 2 O 2 and DA quinone [11,13] .”
BackgroundWakabayashi, N., Dinkova-Kostova, A. T., Holtzclaw, W. D., Kang, M.-I., Kobayashi, A., Yamamoto, M., Kensler, T. W., & Talalay, P. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307301101 · Cited by 986 · cited 1×
“Cysteines at positions 151, 273 and 288 seem to be particularly sensitive to redox changes and to interaction with electrophilic compounds [38,41,47-51] .”
BackgroundCullinan, S. B., Gordan, J. D., Jin, J., Harper, J. W., & Diehl, J. A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.19.8477-8486.2004 · Cited by 986
Clements, C. M., McNally, R. S., Conti, B. J., Mak, T. W., & Ting, J. P.-Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607260103 · Cited by 818 · cited 1×
“[61] has demonstrated a molecular connection between Nrf2 and DJ-1, a gene product that is altered in familiar cases of PD.”
BackgroundExpression of Nrf2 in Neurodegenerative Diseases
Ramsey, C. P., Glass, C. A., Montgomery, M. B., Lindl, K. A., Ritson, G. P., Chia, L. A., Hamilton, R. L., Chu, C. T., & Jordan-Sciutto, K. L. (2007) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/nen.0b013e31802d6da9 · Cited by 760
Tong, K. I., Katoh, Y., Kusunoki, H., Itoh, K., Tanaka, T., & Yamamoto, M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.8.2887-2900.2006 · Cited by 759 · cited 1×
“Lately, a two-site binding (hinge and latch) model was proposed by Hayes’s and Yamamoto’s groups [43-45] to explain the mechanistic interaction between Nrf2 and Keap1 under normal and oxidant stress conditions.”
BackgroundStructural basis for defects of Keap1 activity provoked by its point mutations in lung cancer
Padmanabhan, B., Tong, K. I., Ohta, T., Nakamura, Y., Scharlock, M., Ohtsuji, M., Kang, M.-I., Kobayashi, A., Yokoyama, S., & Yamamoto, M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.013 · Cited by 735 · cited 1×
“Therefore, binding to both hinge and latch sites orients this alpha-helix for ubiquitination [46] .”
Background(2004) · Archives of Neurology · doi:10.1001/archneur.61.7.1044 · Cited by 561 · cited 1×
“With the use of neurofunctional imaging techniques two studies compared the progression of DAergic cell death in patients treated with pramipexole versus levodopa (CALM-PD) [99] and ropinirole versus levodopa (REAL-PET) [100] .”
MethodHaas, R. H., Nasirian, F., Nakano, K., Ward, D., Pay, M., Hill, R., & Shults, C. W. (1995) · Annals of Neurology · doi:10.1002/ana.410370604 · Cited by 435
Spencer, J. P. E., Jenner, P., Daniel, S. E., Lees, A. J., Marsden, D. C., & Halliwell, B. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71052112.x · Cited by 373 · cited 1×
“A mechanism to attenuate the cytotoxic effect of DA quinone is the sequestration with GSH to form 55(-S-glutathionyl-DA, but this involves the expense of GSH, a central molecule to keep redox homeostasis [24] .”
BackgroundBedford, L., Hay, D., Devoy, A., Paine, S., Powe, D. G., Seth, R., Gray, T., Topham, I., Fone, K., Rezvani, N., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2218-08.2008 · Cited by 327 · cited 1×
“Aberrant protein conformations of oxidized or nitrated α -Syn may saturate the proteasome and promote accumulation of misfolded proteins [23] .”
BackgroundLee, J.-M., Shih, A. Y., Murphy, T. H., & Johnson, J. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305204200 · Cited by 308 · cited 1×
“It is a member of the Cap‘n’Collar transcription factor family that regulates the expression of a set of genes with antioxidant response elements (AREs) in their promoters [30-32] .”
BackgroundIntraneuronal dopamine-quinone synthesis: a review
Sulzer, D., & Zecca, L. (1999) · Neurotoxicity Research · doi:10.1007/bf03033289 · Cited by 284
YOUDIM, M. B. H., STEPHENSON, G., & SHACHAR, D. B. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1306.025 · Cited by 233 · cited 1×
“Behavioral and biochemical changes induced by MPTP were attenuated by iron chelating therapy [69] .”
BackgroundGSK3B polymorphisms alter transcription and splicing in Parkinson's disease
Kwok, J. B. J., Hallupp, M., Loy, C. T., Chan, D. K. Y., Woo, J., Mellick, G. D., Buchanan, D. D., Silburn, P. A., Halliday, G. M., & Schofield, P. R. (2005) · Annals of Neurology · doi:10.1002/ana.20691 · Cited by 205 · cited 2×
“observations: i) Akt activity declines with age, which is the main risk factor for sporadic PD [59] ; ii) an association has been reported between PD and single nucleotide polymorphism in the GSK3B gene that results in enhanced GSK-3 β expression and activity [60] .”
Background
Cited by
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
Cuadrado, A., Rojo, A. I., Wells, G., Hayes, J. D., Cousin, S. P., Rumsey, W. L., Attucks, O. C., Franklin, S., Levonen, A.-L., Kensler, T. W., et al. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0008-x · Cited by 1,438
Self-citationStress-activated cap’n’collar transcription factors in aging and human disease
Sykiotis, G. P., & Bohmann, D. (2010) · Science Signaling · doi:10.1126/scisignal.3112re3 · Cited by 776
Rada, P., Rojo, A. I., Chowdhry, S., McMahon, M., Hayes, J. D., & Cuadrado, A. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01204-10 · Cited by 759
Self-citationTranscription Factor NRF2 as a Therapeutic Target for Chronic Diseases: A Systems Medicine Approach
Cuadrado, A., Manda, G., Hassan, A., Alcaraz, M. J., Barbas, C., Daiber, A., Ghezzi, P., León, R., López, M. G., Oliva, B., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014753 · Cited by 632
Self-citationRenoprotective effect of the antioxidant curcumin: Recent findings
Trujillo, J., Chirino, Y. I., Molina-Jijón, E., Andérica-Romero, A. C., Tapia, E., & Pedraza-Chaverrí, J. (2013) · Redox Biology · doi:10.1016/j.redox.2013.09.003 · Cited by 566
Metadata
- Authors
- Cuadrado, A., Moreno-Murciano, P., & Pedraza-Chaverri, J.
- Venue
- Expert Opinion on Therapeutic Targets
- Publisher
- Informa Healthcare
- Published
- 2009-03
- Volume
- 13
- Issue
- 3
- Pages
- 319-329
- ISSN
- 1472-8222 (ISSN-L)
- 1744-7631
- OpenAlex
- W1989373140
- Cited by
- 135
- References
- 23
- FWCI
- 3.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.